Key result
Novel serum MMP-8 ELISA demonstrates diagnostic accuracy comparable to standard IFMA.
Why the study?
Reliable detection of serum MMP-8 levels required laborious and expensive immunofluorometric assay, motivating evaluation of a novel ELISA-assay for acute cardiac diagnostics.
Does a novel ELISA-assay for MMP-8 provide comparable diagnostic accuracy to the standard IFMA in patients with acute coronary syndrome?
Observational (n=2,724)
Does a novel ELISA-assay for MMP-8 provide comparable diagnostic accuracy to the standard IFMA in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
A novel, less laborious ELISA assay for serum MMP-8 demonstrates comparable diagnostic performance to the standard IFMA, offering a potential new tool for cardiovascular disease diagnostics.
Matrix metalloproteinases (MMPs) play a major role in inflammatory processes as they degrade extracellular proteins and modify immune responses. Inflammation is the driving factor in atherogenesis and MMPs, particularly MMP-8, has been linked to atherosclerotic plaque progression. MMP-8 is shown to be strongly associated with cardiovascular diseases (CVDs) and its complications thus providing a potential marker to identify patients at risk. Previously, laborious and expensive immunofluorometric assay (IFMA) was needed to reliably detect MMP-8 levels in serum. In this study, we compared a novel in-house ELISA-assay, dentoELISA, to the standard IFMA in determination of serum MMP-8 concentrations. As a cheaper and non-laborious assay, ELISA proved to be diagnostically as sensitive and specific as the IFMA. ROC statistics showed highly similar areas under the curve for both assays (0.779 versus 0.781). Furthermore, the concentrations measured by ELISA correlated significantly with concentrations determined with IFMA (r = 0.881, P < 0.001). In our study population, MMP-8 levels were significantly higher in the acute coronary syndrome patients (n = 2071) in comparison to reference population without significant coronary artery disease (n = 653). With this background, MMP-8-ELISA could provide interesting new approaches to novel CVD diagnostics.
No takes yet. Share an insight, caveat, or question.
Nieminen et al. (2015) conducted an observational in Acute coronary syndrome (n=2,724). dentoELISA (novel in-house ELISA-assay for MMP-8) vs. Standard immunofluorometric assay (IFMA) was evaluated on Diagnostic accuracy (Area Under the Curve) (r = 0.881, p=< 0.001). A novel ELISA assay for serum MMP-8 demonstrated diagnostic accuracy comparable to the standard IFMA and correlated with IFMA concentrations.
Synapse has enriched 10 related papers. Consider them for comparative context: